Norliqva FDA Approval History
FDA Approved: Yes (First approved February 24, 2022)
Brand name: Norliqva
Generic name: amlodipine besylate
Dosage form: Oral Solution
Company: CMP Pharma, Inc.
Treatment for: High Blood Pressure, Coronary Artery Disease, Angina
Norliqva (amlodipine besylate) is an oral solution formulation of the approved calcium channel blocker amlodipine for the treatment of hypertension and angina in patients with coronary artery disease.
- Norliqva is indicated for the treatment of:
- Hypertension in adults and children 6 years of age and older, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.
- Coronary Artery Disease
- Chronic Stable Angina
- Vasospastic Angina (Prinzmetal's or Variant Angina)
- Angiographically Documented Coronary Artery Disease in patients without heart failure or an ejection fraction <40%.
- Norliqva is supplied as a peppermint flavored oral solution containing amlodipine 1 mg/mL and is administered once daily.
- Common adverse reactions to amlodipine include edema, dizziness, flushing and palpitation.
Development timeline for Norliqva
| Date | Article |
|---|---|
| Feb 28, 2022 | Approval FDA Approves Norliqva (amlodipine) Oral Solution for Hypertension and Coronary Artery Disease |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
